MedTrace Logo

A Retrospective Real-world Study of Abemaciclib in HR+ Breast Cancer

NCT06341283 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2024-05-10

No results posted yet for this study

Summary

The present study will assess real-world clinical outcomes, adverse events and economics from treatment with endocrine therapy(ET) combined with abemaciclib in patients with hormone receptor-positive(HR+) breast cancer.

Conditions

Interventions

DRUG

Abemaciclib and Letrozole/Anastrozole

Take the treatment with Abemaciclib and Letrozole/Anastrozole at the same time.

DRUG

Letrozole or Anastrozole

Take the treatment with Letrozole or Anastrozole.

DRUG

Abemaciclib and Fulvestrant

Take the treatment with Abemaciclib and Fulvestrant at the same time.

DRUG

Fulvestrant

Take the treatment with Fulvestrant only.

Sponsors & Collaborators

  • The Affiliated Hospital of Qingdao University

    lead OTHER

Principal Investigators

  • Yu Cao, docter · The Affiliated Hospital of Qingdao University

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-01
Primary Completion
2024-12-31
Completion
2025-07-01
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06341283 on ClinicalTrials.gov